EA035098B1 - Способ лечения рецидивирующей и/или рефрактерной множественной миеломы - Google Patents
Способ лечения рецидивирующей и/или рефрактерной множественной миеломы Download PDFInfo
- Publication number
- EA035098B1 EA035098B1 EA201690905A EA201690905A EA035098B1 EA 035098 B1 EA035098 B1 EA 035098B1 EA 201690905 A EA201690905 A EA 201690905A EA 201690905 A EA201690905 A EA 201690905A EA 035098 B1 EA035098 B1 EA 035098B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- seq
- antibodies
- dose
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306220 | 2014-07-31 | ||
| PCT/US2014/063380 WO2015066450A1 (en) | 2013-10-31 | 2014-10-31 | Specific anti-cd38 antibodies for treating human cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201690905A1 EA201690905A1 (ru) | 2016-08-31 |
| EA035098B1 true EA035098B1 (ru) | 2020-04-27 |
Family
ID=51266255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201690905A EA035098B1 (ru) | 2014-07-31 | 2014-10-31 | Способ лечения рецидивирующей и/или рефрактерной множественной миеломы |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20150118251A1 (https=) |
| EP (2) | EP3805266A1 (https=) |
| JP (3) | JP2016536314A (https=) |
| KR (1) | KR20160077155A (https=) |
| CN (1) | CN106103481A (https=) |
| AU (1) | AU2014342103B2 (https=) |
| BR (1) | BR112016009403A2 (https=) |
| CA (1) | CA2927099A1 (https=) |
| CR (1) | CR20160186A (https=) |
| EA (1) | EA035098B1 (https=) |
| IL (1) | IL245196B (https=) |
| MA (2) | MA44560B2 (https=) |
| MX (1) | MX373301B (https=) |
| NZ (1) | NZ719784A (https=) |
| PL (1) | PL3063173T3 (https=) |
| PT (1) | PT3063173T (https=) |
| SG (2) | SG10201803288RA (https=) |
| TN (1) | TN2016000142A1 (https=) |
| TW (1) | TW201522378A (https=) |
| WO (1) | WO2015066450A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| SG10201913777XA (en) * | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| PH12017500442B1 (en) | 2014-09-09 | 2023-05-24 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| CN107406506A (zh) | 2014-12-04 | 2017-11-28 | 詹森生物科技公司 | 用于治疗急性髓系白血病的抗cd38抗体 |
| HUE054271T2 (hu) * | 2015-05-13 | 2021-08-30 | Morphosys Ag | Mielóma Multiplex (MM) kezelése |
| EA201792546A1 (ru) | 2015-05-20 | 2018-04-30 | Янссен Байотек, Инк. | Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей |
| EP3303373B1 (en) | 2015-05-30 | 2020-04-08 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
| WO2016201337A1 (en) * | 2015-06-12 | 2016-12-15 | Immungene, Inc. | Engineered antibody-interferon fusion molecules for the treatment of glucose-regulated protein 94 (grp94) expressing cancers |
| IL256242B2 (en) | 2015-06-22 | 2024-09-01 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| CA3004152C (en) | 2015-11-03 | 2024-04-16 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| WO2017149122A1 (en) | 2016-03-04 | 2017-09-08 | Morphosys Ag | Clinical assessment of m-protein response in multiple myeloma |
| KR20250175345A (ko) | 2016-06-21 | 2025-12-16 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| MA45674A (fr) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
| PE20241349A1 (es) | 2016-09-14 | 2024-07-03 | Teneobio Inc | Anticuerpos de union a cd3 |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| KR20250007003A (ko) | 2017-06-20 | 2025-01-13 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| CN110945026B (zh) | 2017-06-20 | 2024-03-19 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
| WO2019031444A1 (ja) * | 2017-08-07 | 2019-02-14 | 国立大学法人九州大学 | 細胞集団における特異的結合物質の占有率を測定する方法 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| EP3681908A1 (en) * | 2017-09-13 | 2020-07-22 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
| MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
| CA3080109A1 (en) | 2017-11-03 | 2019-05-09 | Sorrento Therapeutics, Inc. | Cd38-directed chimeric antigen receptor constructs |
| KR20210006321A (ko) | 2018-01-12 | 2021-01-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 항-cd38 항체의 피하 투여 |
| KR20250117714A (ko) * | 2018-03-28 | 2025-08-05 | 다케다 야쿠힌 고교 가부시키가이샤 | 항-cd38 항체의 피하 투약 |
| KR20210030411A (ko) * | 2018-07-10 | 2021-03-17 | 사노피 | Cd38 및 tgf-베타를 표적으로 하는 암에 대한 병용 요법 |
| KR20210104736A (ko) | 2018-12-14 | 2021-08-25 | 모르포시스 아게 | 항체 제형 |
| IL286482B2 (en) * | 2019-03-21 | 2025-01-01 | Gamida Cell Ltd | Cultured NK cell fractions for use in combination therapy |
| WO2020206330A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| CR20210622A (es) | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| CN112876563B (zh) * | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技（成都）有限公司 | 药物组合物及其制备方法和应用 |
| IL293563A (en) | 2019-12-05 | 2022-08-01 | Sanofi Aventis Us Llc | Formulations of anti-cd38 antibodies for subcutaneous administration |
| CN115698065A (zh) * | 2019-12-06 | 2023-02-03 | 赛诺菲-安万特美国有限责任公司 | 艾萨妥昔单抗用于治疗复发性和/或难治性多发性骨髓瘤的用途 |
| CN116670285A (zh) * | 2020-06-23 | 2023-08-29 | 江苏康缘药业股份有限公司 | 抗cd38抗体及其用途 |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| TW202432177A (zh) * | 2022-10-31 | 2024-08-16 | 丹麥商珍美寶股份有限公司 | Ｃｄ３８抗體及其用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013059885A2 (en) * | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Polypeptide constructs and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CN1976950B (zh) * | 2004-02-06 | 2012-08-29 | 莫佛塞斯公司 | 抗cd38人抗体及其用途 |
| JP5225069B2 (ja) * | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| TW200745162A (en) * | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| WO2008037257A2 (en) * | 2006-09-26 | 2008-04-03 | Genmab A/S | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2191843A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| SG10201913777XA (en) * | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
-
2014
- 2014-10-31 US US14/529,719 patent/US20150118251A1/en not_active Abandoned
- 2014-10-31 SG SG10201803288RA patent/SG10201803288RA/en unknown
- 2014-10-31 SG SG11201603088RA patent/SG11201603088RA/en unknown
- 2014-10-31 PT PT147990899T patent/PT3063173T/pt unknown
- 2014-10-31 CN CN201480071448.0A patent/CN106103481A/zh active Pending
- 2014-10-31 WO PCT/US2014/063380 patent/WO2015066450A1/en not_active Ceased
- 2014-10-31 JP JP2016527374A patent/JP2016536314A/ja active Pending
- 2014-10-31 EP EP20188077.0A patent/EP3805266A1/en not_active Withdrawn
- 2014-10-31 TW TW103137932A patent/TW201522378A/zh unknown
- 2014-10-31 PL PL14799089T patent/PL3063173T3/pl unknown
- 2014-10-31 CA CA2927099A patent/CA2927099A1/en not_active Abandoned
- 2014-10-31 MA MA44560A patent/MA44560B2/fr unknown
- 2014-10-31 TN TN2016000142A patent/TN2016000142A1/en unknown
- 2014-10-31 EA EA201690905A patent/EA035098B1/ru not_active IP Right Cessation
- 2014-10-31 MX MX2016005666A patent/MX373301B/es active IP Right Grant
- 2014-10-31 BR BR112016009403A patent/BR112016009403A2/pt not_active Application Discontinuation
- 2014-10-31 NZ NZ719784A patent/NZ719784A/en unknown
- 2014-10-31 AU AU2014342103A patent/AU2014342103B2/en active Active
- 2014-10-31 MA MA39070A patent/MA39070A1/fr unknown
- 2014-10-31 EP EP14799089.9A patent/EP3063173B1/en active Active
- 2014-10-31 KR KR1020167013974A patent/KR20160077155A/ko not_active Ceased
-
2016
- 2016-04-19 IL IL245196A patent/IL245196B/en active IP Right Grant
- 2016-04-21 CR CR20160186A patent/CR20160186A/es unknown
-
2017
- 2017-04-05 US US15/479,500 patent/US20180022814A1/en not_active Abandoned
-
2023
- 2023-05-24 JP JP2023085105A patent/JP2023109927A/ja active Pending
-
2025
- 2025-05-07 JP JP2025077126A patent/JP2025139586A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013059885A2 (en) * | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Polypeptide constructs and uses thereof |
Non-Patent Citations (6)
| Title |
|---|
| CHILLEMI A, ZACCARELLO G, QUARONA V, FERRACIN M, GHIMENTI C, MASSAIA M, HORENSTEIN AL, MALAVASI F.: "Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule.", MOLECULAR MEDICINE, FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH, WASHINGTON, DC; US, vol. 19, no. 1, 1 May 2013 (2013-05-01), WASHINGTON, DC; US, pages 99 - 108, XP002735274, ISSN: 1076-1551, DOI: 10.2119/molmed.2013.00009 * |
| MARTIN T , BAZ R, BENSON D, LENDVAI N, VIJ R, CHARPENTIER E, HSU K: "A PHASE IB DOSE ESCALATION TRIAL OF SAR650984 (ANTI-CD-38 MAB) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA", HAEMATOLOGICA, FONDAZIONE FERRATA STORTI, IT, vol. 99, no. Suppl. 1, P373, 1 June 2014 (2014-06-01), IT, pages 114, XP002735276, ISSN: 0390-6078 * |
| P RICHARDSON, H LOKHORST, A PALUMBO, H NAHI, J LAUBACH, PETER GIMSING, S LISBY, A CAKANA, N C BRUN, TORBEN PLESNER: "Daratumumab. Anti-CD38 monoclonal antibody, treatment of multiple myeloma", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, vol. 38, no. 8, 1 August 2013 (2013-08-01), ES, pages 545 - 554, XP002735278, ISSN: 0377-8282, DOI: 10.1358/dof.2013.038.08.2025424 * |
| Sanofi: "Dose Escalation Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies", ClinicalTrials.gov arhivve, 15 October 2013 (2013-10-15), XP002735279, Retrieved from the Internet: URL:https://clinicaltrials.gov/archive/NCT01084252/2013_10_15 [retrieved on 2015-01-30] the whole document * |
| SATHISH GOPALAKRISHNAN, DARYL TAN: "Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies", BLOOD AND LYMPHATIC CANCER: TARGETS AND THERAPY, DOVE MEDICAL PRESS LTD., GB, vol. 2013, no. 3, 18 April 2013 (2013-04-18), GB, pages 19 - 24, XP002735277, ISSN: 1179-9889, DOI: 10.2147/BLCTT.S29567 * |
| THOMAS G MARTIN , STEPHEN A. STRICKLAND, MARTHA GLENN, WEI ZHENG, NIKKI DASKALAKIS, JOSEPH R. MIKHAEL: "SAR650984, a CD38 Monoclonal Antibody In Patients With Selected CD38+ Hematological Malignancies- Data From a Dose-Escalation Phase I Study", BLOOD, THE AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 122, no. 21, 284, 15 November 2013 (2013-11-15), US, pages 284, XP002735275, ISSN: 0006-4971 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL245196A0 (en) | 2016-06-30 |
| CN106103481A (zh) | 2016-11-09 |
| PL3063173T3 (pl) | 2021-01-11 |
| JP2025139586A (ja) | 2025-09-26 |
| NZ719784A (en) | 2022-02-25 |
| EA201690905A1 (ru) | 2016-08-31 |
| SG10201803288RA (en) | 2018-05-30 |
| MA44560B2 (fr) | 2021-01-29 |
| PT3063173T (pt) | 2020-10-20 |
| AU2014342103B2 (en) | 2020-06-04 |
| AU2014342103A1 (en) | 2016-05-26 |
| TN2016000142A1 (en) | 2017-10-06 |
| JP2016536314A (ja) | 2016-11-24 |
| CR20160186A (es) | 2016-06-13 |
| WO2015066450A1 (en) | 2015-05-07 |
| US20180022814A1 (en) | 2018-01-25 |
| US20150118251A1 (en) | 2015-04-30 |
| JP2023109927A (ja) | 2023-08-08 |
| EP3063173A1 (en) | 2016-09-07 |
| IL245196B (en) | 2021-04-29 |
| MX2016005666A (es) | 2016-07-14 |
| BR112016009403A2 (pt) | 2017-09-19 |
| MX373301B (es) | 2020-04-24 |
| MA44560B1 (fr) | 2020-06-30 |
| EP3063173B1 (en) | 2020-07-29 |
| TW201522378A (zh) | 2015-06-16 |
| SG11201603088RA (en) | 2016-05-30 |
| CA2927099A1 (en) | 2015-05-07 |
| MA39070A1 (fr) | 2017-11-30 |
| KR20160077155A (ko) | 2016-07-01 |
| MA44560A1 (fr) | 2019-09-30 |
| EP3805266A1 (en) | 2021-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014342103B2 (en) | Specific anti-CD38 antibodies for treating human cancers | |
| JP6914283B2 (ja) | ヒトのがんを治療するための特異的抗ｃｄ３８抗体 | |
| KR20160097336A (ko) | 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법 | |
| EP3092252B1 (en) | Antibody targeting cell surface deposited complement protein c3d and use thereof | |
| JP7538131B2 (ja) | 抗ｃｄ７９ｂ抗体、その抗原結合フラグメントおよびそれらの医薬用途 | |
| EP4292611A1 (en) | Anti-cd112r antibody and use thereof | |
| TW202302650A (zh) | 針對dll3的結合分子及其應用 | |
| US12173081B2 (en) | CD19/CD38 multispecific antibodies | |
| WO2019076277A1 (zh) | 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途 | |
| JP2022529340A (ja) | ヒトｃｄ４７を標的とする抗体 | |
| CN114106182A (zh) | 抗tigit的抗体及其用途 | |
| TW202345895A (zh) | 在用於治療瀰漫性大型ｂ細胞淋巴瘤之組合療法中針對ｃｄ３和ｃｄ２０之雙特異性抗體 | |
| US20230365714A1 (en) | Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3 | |
| JP2024517985A (ja) | 抗－ＣＤ３００ｃモノクローナル抗体及びその癌の予防または治療用バイオマーカー | |
| CN113150150A (zh) | Tim3结合分子及其应用 | |
| CN113368232B (zh) | 多特异性抗原结合蛋白及其应用 | |
| WO2026033458A1 (en) | DOSES AND PHARMACEUTICAL COMPOSITIONS OF A CD33 X Vδ2 BISPECIFIC ANTIBODY FOR THE TREATMENT OF CANCER | |
| HK1223116B (en) | Specific anti-cd38 antibodies for treating human cancers | |
| TW202430210A (zh) | 用於治療癌症之btn3a活化抗體、bcl2抑制劑及去甲基化劑之組合 | |
| TW202537974A (zh) | Ｔｒｇｖ９結合蛋白及其醫藥用途 | |
| HK40046552B (zh) | 对cd3特异性的抗体及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |